Quillien 2016.

Study characteristics
Study design	Cohort
Study setting	Setting: 8 centres Country: France Dates: enrolled between March 2009 and June 2011
Selection of participants	Inclusion criteria: histologically confirmed de novo‐GBM, aged 18–70 years, presented with no contraindications as dictated by the Stupp protocol and not included in experimental therapeutic protocols
Participant characteristics	Sample size: 139 (deaths: 119) Age: median 55.9; range 23.0–71.0 years Sex: 70.5% men KPS: median NR; KPS 90–100: 41 (29.5%); KPS 70–80: 76 (54.7%); KPS < 70: 20 (14.4%); KPS missing: 2 (1.4%)
Tumour characteristics	GBM: 100% First diagnosis: 100% Biopsy: 14.4%; subtotal resection: 29.5%; total resection: 56.1% IDH1 wild‐type: NR; IDH2 wild‐type: NR
Treatment regimen	Stupp protocol
MGMT promoter methylation tests implemented	PSQ, SQ‐MSP
Dates and follow‐up	Timing of MGMT assessment: not explicitly reported but presumably on tissue harvested during biopsy/resection Start time for follow‐up: NR; follow‐up: median NR; range NR
Notes